These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis. Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783 [TBL] [Abstract][Full Text] [Related]
6. Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure. Wirtz HS; Sheer R; Honarpour N; Casebeer AW; Simmons JD; Kurtz CE; Pasquale MK; Globe G J Am Heart Assoc; 2020 Aug; 9(16):e015042. PubMed ID: 32805181 [TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
8. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154 [TBL] [Abstract][Full Text] [Related]
9. Design of a multicentre randomized controlled trial to assess the safety and efficacy of dose titration by specialized nurses in patients with heart failure. ETIFIC study protocol. Oyanguren J; García-Garrido L; Nebot Margalef M; Lekuona I; Comin-Colet J; Manito N; Roure J; Ruiz Rodriguez P; Enjuanes C; Latorre P; Torcal Laguna J; García-Gutiérrez S; ESC Heart Fail; 2017 Nov; 4(4):507-519. PubMed ID: 29154427 [TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns, Outcomes, and Persistence to Newly Started Heart Failure Medications in Patients with Worsening Heart Failure: A Cohort Study from the United States and Germany. Michel A; Lecomte C; Ohlmeier C; Raad H; Basedow F; Haeckl D; Beier D; Evers T Am J Cardiovasc Drugs; 2024 May; 24(3):409-418. PubMed ID: 38573461 [TBL] [Abstract][Full Text] [Related]
11. Postponement of Death by Pharmacological Heart Failure Treatment: A Meta-Analysis of Randomized Clinical Trials. Hansen MR; Hróbjartsson A; Videbæk L; Ennis ZN; Pareek M; Paulsen NH; Broe M; Olesen M; Pottegård A; Damkier P; Hallas J Am J Med; 2020 Jun; 133(6):e280-e289. PubMed ID: 32173347 [TBL] [Abstract][Full Text] [Related]
12. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials. Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370 [TBL] [Abstract][Full Text] [Related]
14. Disease management interventions for heart failure. Takeda A; Martin N; Taylor RS; Taylor SJ Cochrane Database Syst Rev; 2019 Jan; 1(1):CD002752. PubMed ID: 30620776 [TBL] [Abstract][Full Text] [Related]
15. The effects of adding angiotensin receptor neprilysin inhibitors to usual care in patients with heart failure: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Nielsen EE; Feinberg J; Raymond I; Olsen MH; Steensgaard-Hansen FV; Jakobsen JC Syst Rev; 2019 Oct; 8(1):251. PubMed ID: 31672170 [TBL] [Abstract][Full Text] [Related]
16. Effect of Optimizing Guideline-Directed Medical Therapy Before Discharge on Mortality and Heart Failure Readmission in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. Yamaguchi T; Kitai T; Miyamoto T; Kagiyama N; Okumura T; Kida K; Oishi S; Akiyama E; Suzuki S; Yamamoto M; Yamaguchi J; Iwai T; Hijikata S; Masuda R; Miyazaki R; Hara N; Nagata Y; Nozato T; Matsue Y Am J Cardiol; 2018 Apr; 121(8):969-974. PubMed ID: 29477488 [TBL] [Abstract][Full Text] [Related]
17. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis. Xiang B; Zhang R; Wu X; Zhou X JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813 [TBL] [Abstract][Full Text] [Related]
18. Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases. Kruik-Kollöffel WJ; van der Palen J; Doggen CJM; van Maaren MC; Kruik HJ; Heintjes EM; Movig KLL; Linssen GCM PLoS One; 2020; 15(12):e0244231. PubMed ID: 33351823 [TBL] [Abstract][Full Text] [Related]
19. Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction. Batchelor RJ; Nan Tie E; Romero L; Hopper I; Kaye DM Am J Cardiol; 2023 Feb; 188():52-60. PubMed ID: 36473305 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews. Al-Gobari M; Al-Aqeel S; Gueyffier F; Burnand B BMJ Open; 2018 Jul; 8(7):e021108. PubMed ID: 30056380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]